Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

TherapeuticsMD (TXMD) Short-Term Debt repayments (2019)

TherapeuticsMD filings provide 3 years of Short-Term Debt repayments readings, the most recent being -$281.0 for Q2 2019.

On a quarterly basis, Short-Term Debt repayments changed N/A to -$281.0 in Q2 2019 year-over-year; TTM through Dec 2019 was -$281.0, a N/A change, with the full-year FY2019 number at $81.7 million, changed N/A from a year prior.
Short-Term Debt repayments hit -$281.0 in Q2 2019 for TherapeuticsMD, down from $399265.0 in the prior quarter.
In the past five years, Short-Term Debt repayments ranged from a high of -$281.0 in Q2 2019 to a low of -$281.0 in Q2 2019.